Durvalumab: A Review in Extensive-Stage SCLC
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-021-00843-0
Abstract: Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small… read more here.
Keywords: chemotherapy; combination; durvalumab; extensive stage ... See more keywords